var data={"title":"Nafarelin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Nafarelin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6618?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=nafarelin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Nafarelin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199096\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Synarel</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199097\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Synarel</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199127\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Gonadotropin Releasing Hormone Agonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199099\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endometriosis:</b> Intranasal: Females: One spray (200 mcg) into 1 nostril each morning and 1 spray (200 mcg) into the other nostril each evening starting between days 2 and 4 of menstrual cycle  (total: 2 sprays [400 mcg] daily). If regular menstruation persists after 2 months of therapy, may increase dose to 2 sprays (400 mcg; 1 spray in each nostril) in the morning and evening (total: 4 sprays [800 mcg] daily). Total duration of therapy should not exceed 6 months due to decreases in bone mineral density; re-treatment is not recommended by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199114\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Central precocious puberty:</b> Intranasal:  Males/Females: (US labeling): Two sprays (400 mcg) into each nostril in the morning and 2 sprays (400 mcg) into each nostril in the evening (total: 8 sprays [1,600 mcg] daily). If inadequate suppression, may increase dose to 3 sprays (600 mcg) into alternating nostrils 3 times daily (total: 9 sprays [1,800 mcg] daily). Continue therapy until resumption of puberty is desired.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199100\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20210043\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20210044\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199083\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Nasal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Synarel: 2 mg/mL (8 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199070\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50184180\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Synarel: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019886s033s035lbl.pdf#page=28&amp;token=xTpJRhzOnQq+dZFdUrrA7cUMYwQ4gqD4m+alH6WxU//rcNJyWweHxjE3TVAY0FePScsv3+b55IBbCAMmnFAXsblnuq+1FG7IyQpAMpNsUxH4vhpAIz2VPjcQCDjdBp8B&amp;TOPIC_ID=9673\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019886s033s035lbl.pdf#page=28</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F803173\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Nasal spray: Allow ~30 seconds to elapse between sprays. Sneezing during or immediately after dosing should be avoided (may decrease drug absorption). Do not use a topical nasal decongestant for at least 2 hours (US labeling) or at least 30 minutes (Canadian labeling) after nafarelin use. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132669\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 3]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, and (if liquid that could splash) eye/face protection for administration of a topical product; if there is potential for inhalation, respiratory protection is recommended (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199084\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Central precocious puberty:</b> Treatment of central precocious puberty (CPP) (gonadotropin-dependent precocious puberty) in children of both sexes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Endometriosis:</b> Management of endometriosis, including pain relief and reduction of endometriotic lesions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199133\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Nafarelin may be confused with Anafranil, enalapril</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199077\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events may be more frequent in the first 6 weeks of treatment due to stimulation of the pituitary-gonadal axis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CPP:</b> 1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Emotional lability (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Acne vulgaris (10%), hypertrichosis (transient, pubic region: 5%), body odor (4%), seborrhea (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Breast hypertrophy (8%; transient), vaginal hemorrhage (8%), hot flashes (3%; transient), vaginal discharge (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction (3%; including chest pain, pruritus, dyspnea, skin rash)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Rhinitis (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endometriosis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central nervous system: Headache (18%), emotional lability (16%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dermatologic: Acne vulgaris (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Endocrine &amp; metabolic: Hot flash (90%), decreased libido (23%), hyperphosphatemia (10% to 15%), hypocalcemia (10% to 15%), hypertriglyceridemia (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Genitourinary: Vaginal dryness (19%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hematologic &amp; oncologic: Change in WBC count (10% to 15%; decreased), eosinophilia (10% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cardiovascular: Edema (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central nervous system: Insomnia (8%), depression (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dermatologic: Hirsutism (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Endocrine &amp; metabolic: Breast atrophy (10%), hypercholesterolemia (6%), increased libido (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gastrointestinal: Weight gain (8%), weight loss (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neuromuscular &amp; skeletal: Myalgia (10%), decreased bone mineral density</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Respiratory: Nasal mucosa irritation (10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;1%, postmarketing, and/or case reports (any indication): Arterial thromboembolism, arthralgia, breast engorgement, chloasma, eye pain, hepatic injury, increased serum ALT, increased serum AST, lactation, maculopapular rash, palpitations, paresthesia, pituitary apoplexy, seizures, venous thromboembolism, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199087\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to gonadotropin-releasing hormone (GnRH), GnRH-agonist analogs, or any component of the formulation; undiagnosed abnormal vaginal bleeding; pregnant women or those who may become pregnant; breast-feeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199074\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Decreased bone density: Has been reported and may be irreversible. Use with caution in patients with risk factors for bone loss (eg, chronic alcohol use, anticonvulsant or corticosteroid therapy, family history of osteoporosis). Repeat courses are not recommended in patients with major risk factors for bone loss.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ovarian cysts: May occur within the first 2 months of therapy and may occur more commonly in women with polycystic ovarian disease. These cysts may resolve spontaneously, generally by about 4 to 6 weeks of therapy, but sometimes require discontinuation of therapy and/or surgical intervention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pituitary apoplexy: Rare cases of pituitary apoplexy (frequently secondary to pituitary adenoma) have been observed with GnRH agonist administration (onset from 1 hour to usually &lt;2 weeks); may present as sudden headache, vomiting, visual or mental status changes, and infrequently cardiovascular collapse; immediate medical attention may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric events: Emotional lability, such as crying, irritability, impatience, anger, and aggression, has been reported in patients taking GnRH agonists. Depression, including rare reports of suicidal ideation and attempt, has been reported for GnRH agonists in children treated for CPP; many of these patients had a history of psychiatric illness or other comorbidities with an increased risk of depression. Monitor for development or worsening of psychiatric symptoms, including depression, during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Have been observed in patients receiving GnRH agonists; patients with a history of seizures, cerebrovascular disorders, CNS anomalies/tumors, and patients on concomitant medications that have been associated with seizures are at increased risk; has also been reported in patients without risk factors.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CPP use: When used for the treatment of CPP, some signs of puberty (eg vaginal bleeding, breast enlargement) may occur but should resolve within the first 2 months of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Endometriosis: Experience with nafarelin for the management of endometriosis has been limited to women 18 years and older treated for 6 months; retreatment is not recommended since safety data is not available for use &gt;6 months.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299735\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199078\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9673&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Choline C 11: Luteinizing Hormone-Releasing Hormone Analogs may diminish the therapeutic effect of Choline C 11. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corifollitropin Alfa: Luteinizing Hormone-Releasing Hormone Analogs may enhance the therapeutic effect of Corifollitropin Alfa. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indium 111 Capromab Pendetide: Luteinizing Hormone-Releasing Hormone Analogs may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199080\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2929271\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Adverse events were observed in some animal reproduction studies. Use is contraindicated in pregnant women and pregnancy should be excluded prior to initiating treatment. Ovulation is inhibited and menstruation is stopped when used appropriately for the treatment of endometriosis, however contraception is not assured. Nonhormonal contraception is recommended. There is no evidence that pregnancy rates are enhanced or adversely affected by use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20616394\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if nafarelin is excreted in breast milk. Use in lactating women is contraindicated by the manufacturer. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2929987\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CPP: Bone mineral density, GnRH testing (blood LH and FSH levels), measurement of bone age, Tanner staging; monitor for development or worsening of psychiatric symptoms, including depression.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endometriosis: Menstruation, vaginal bleeding or spotting which persists after 2 months of treatment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199073\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Potent synthetic decapeptide analogue of gonadotropin-releasing hormone (GnRH; LHRH) which is approximately 200 times more potent than GnRH in terms of pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Effects on the pituitary gland and sex hormones are dependent upon its length of administration. After acute administration, an initial stimulation of the release of LH and FSH from the pituitary is observed; an increase in androgens and estrogens subsequently follows. Continued administration of nafarelin, however, suppresses gonadotrope responsiveness to endogenous GnRH resulting in reduced secretion of LH and FSH and, secondarily, decreased ovarian and testicular steroid production.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199086\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding, plasma: ~80%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Degraded by peptidase; forms metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: ~1% to 6%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: ~3 hours; Metabolites: ~86 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: 10 to 45 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (44% to 55%, ~3% as unchanged drug); feces (19% to 44%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199089\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Synarel Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/mL (8 mL): $3,403.84</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199090\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Nasanyl (JP);</li>\n      <li>Nasarel (IN);</li>\n      <li>Synarel (AU, BB, BE, BF, BG, BJ, BR, CI, CZ, DE, ES, ET, FR, GB, GH, GM, GN, GR, HN, HU, IE, KE, LR, LU, MA, ML, MR, MU, MW, MX, NE, NG, NL, PT, RU, SC, SD, SG, SI, SL, SN, TN, TR, TW, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Synarela (DK, FI, IS, NO, SE);</li>\n      <li>Synrelin (AR);</li>\n      <li>Synrelina (CH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hornstein MD, Yuzpe AA, Burry K, et al, &ldquo;Retreatment With Nafarelin for Recurrent Endometriosis Symptoms: Efficacy, Safety and Bone Mineral Density,&rdquo; <i>Fertil Steril</i>, 1997, 67(6):1013-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nafarelin-drug-information/abstract-text/9176437/pubmed\" target=\"_blank\" id=\"9176437\">9176437</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Synarel (nafarelin) [prescribing information]. New York, NY: Pfizer; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Synarel (nafarelin) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; January 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tahara M, Matsuoka T, Yokoi T, et al, &ldquo;Treatment of Endometriosis With a Decreasing Dosage of a Gonadotropin-Releasing Hormone Agonist (Nafarelin): A Pilot Study With Low-Dose Agonist Therapy (&ldquo;Draw-Back&rdquo; Therapy),&rdquo; <i>Fertil Steril</i>, 2000, 73(4):799-804.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nafarelin-drug-information/abstract-text/10731543/pubmed\" target=\"_blank\" id=\"10731543\">10731543</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9673 Version 103.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F199096\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F199097\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F199127\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F199099\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F199114\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F199100\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F20210043\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F20210044\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F199083\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F199070\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F50184180\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F803173\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132669\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F199084\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F199133\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F199077\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F199087\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F199074\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299735\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F199078\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F199080\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2929271\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20616394\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F2929987\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F199073\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F199086\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F199089\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F199090\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9673|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=nafarelin-patient-drug-information\" class=\"drug drug_patient\">Nafarelin: Patient drug information</a></li></ul></div></div>","javascript":null}